IceCure Medical Ltd (ICCM)
NASDAQ: ICCM · Real-Time Price · USD
2.300
+0.010 (0.44%)
At close: Aug 28, 2026, 4:00 PM EDT
2.210
-0.090 (-3.91%)
After-hours: Aug 28, 2026, 7:44 PM EDT
IceCure Medical Employees
As of December 31, 2025, IceCure Medical had 69 total employees, including 67 full-time and 2 part-time employees. The number of employees increased by 3 or 4.55% compared to the previous year.
Employees
69
Change (1Y)
3
Growth (1Y)
4.55%
Revenue / Employee
$57,203
Profits / Employee
-$244,638
Market Cap
7.88M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 69 | 3 | 4.55% | 67 | 2 |
| Dec 31, 2024 | 66 | -11 | -14.29% | 64 | 2 |
| Dec 31, 2023 | 77 | 5 | 6.94% | 71 | 6 |
| Dec 31, 2022 | 72 | 8 | 12.50% | 65 | 7 |
| Dec 31, 2021 | 64 | 17 | 36.17% | 55 | 9 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Trinity Biotech | 287 |
| WORK Medical Technology Group LTD | 238 |
| Co-Diagnostics | 115 |
| VolitionRx | 57 |
| Intelligent Bio Solutions | 55 |
| Biomerica | 54 |
| Beyond Air | 54 |
| enVVeno Medical | 33 |
ICCM News
- 5 days ago - IceCure Medical announces distribution agreement with Scovas Medical - TheFly
- 5 days ago - IceCure Signs Exclusive Distribution Agreement for ProSense® Cryoablation Systems in the Netherlands - PRNewsWire
- 9 days ago - IceCure Medical’s study for ProSense cryoablation approved by West Cancer Center - TheFly
- 9 days ago - West Cancer Center Receives IRB Approval to Commence IceCure's ChoICE Study for Breast Cancer Cryoablation - PRNewsWire
- 12 days ago - IceCure Medical highlights two publications supporting ProSense’s cryoablation - TheFly
- 16 days ago - IceCure Highlights Two New Peer-Reviewed Publications Supporting Cryoablation in Breast Cancer Treatment De-Escalation - PRNewsWire
- 17 days ago - IceCure Medical Earnings Call Transcript: Q2 2026 - Transcripts
- 17 days ago - IceCure Medical Earnings release: Q2 2026 - Filings